In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
« Il y a urgence à agir » : le gouvernement veut cadrer l’usage de l’IA dans la fonction publique Face au « danger » d’une technologie « clandestine », notamment, l’exécutif veut mener une « ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results